This randomized clinical trial compares clinically guided vs genotype-guided dosing to assess whether it improves the safety of warfarin initiation in patients undergoing elective hip or knee arthroplasty.
This JAMA Clinical Guidelines Synopsis summarizes the American College of Chest Physicians’ 2016 recommendations on antithrombotic therapy for venous thromboembolism (VTE).
This commentary discusses a cohort study published in JAMA Surgery that investigated the association between inpatient surveillance for venous thromboembolism and risk of postdischarge venous thromboembolism.
This JAMA Clinical Guidelines Synopsis summarizes the American Heart Association’s 2014 scientific statement on prevention, diagnosis, and treatment of postthrombotic syndrome.
This Viewpoint discusses low public awareness about risk factors for and symptoms of venous thromboembolism and proposes quality initiatives that might improve recognition of venous thromboembolism and outcomes for patients.
This randomized trial compares the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic venous thromboembolism in patients with active cancer.
This JAMA Clinical Evidence Synopsis describes the association of long-term duration vs short-term duration of vitamin K antagonist therapy among patients with venous thromboembolism.
This randomized trial compared the efficacy and safety of 6 vs 24 months of warfarin treatment for preventing recurrent thromboembolism in patients with a first episode of symptomatic unprovoked pulmonary embolism.
This randomized trial compares the effects of a retrievable inferior vena cava filter plus anticoagulation with anticoagulation alone for prevention of recurrent pulmonary embolism in patients hospitalized with venous thromboembolism.
This Viewpoint discusses how the Center for Medicare and Medicaid’s use of Patient Safety Indicator-90 in pay-for-performance programs falls short in its attempt to accurately and fairly measure patient harm.
This prospective economic evaluation reports that use of LMW heparin for venous thromboembolism prophylaxis in critically ill patients was more effective than unfractionated heparin, with similar or lower costs.
You currently have no searches saved.